Microbiota-Derived SCFAs in Multiple Sclerosis: From Immune Priming to Neurodegeneration

No abstract is available for this paper.

• Publication year

  2025

• Venue

  Molecular Neurobiology

• Publication date

  2025-11-12

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1007/s12035-025-05348-9PMID 41222739
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The gut microbiota-immune-brain axis: Therapeutic implications

  2025cited by this paper
• Gut–Brain Axis and Brain Microbiome Interactions from a Medical Perspective

  2025cited by this paper
• Epidemiology of Multiple Sclerosis: Global, Regional, National and Sub-National-Level Estimates and Future Projections

  2025cited by this paper
• The role of short-chain fatty acid in metabolic syndrome and its complications: focusing on immunity and inflammation

  2025cited by this paper
• Clinical Management in Multiple Sclerosis

  2025cited by this paper
• Alterations in Gut Microbiome-Host Relationships After Immune Perturbation in Patients With Multiple Sclerosis

  2025cited by this paper
• The microbiota-gut-brain-axis theory: role of gut microbiota modulators (GMMs) in gastrointestinal, neurological, and mental health disorders

  2025cited by this paper
• Progressive multiple sclerosis: Evaluating current therapies and exploring future treatment strategies

  2025cited by this paper
• Role of dietary fiber and short-chain fatty acids in preventing neurodegenerative diseases through the gut-brain axis

  2025cited by this paper
• Microbiota-Driven Mechanisms in Multiple Sclerosis: Pathogenesis, Therapeutic Strategies, and Biomarker Potential

  2025cited by this paper
• Gut-Microbiota-Derived Metabolites and Probiotic Strategies in Colorectal Cancer: Implications for Disease Modulation and Precision Therapy

  2025cited by this paper
• Exploring the complex interplay: insulin resistance and gut microbiome dysbiosis in multiple sclerosis.

  2025cited by this paper
• Association Between Gastrointestinal Symptoms and Disease Severity in Multiple Sclerosis Patients

  2025cited by this paper
• Therapeutic Potential of Short-Chain Fatty Acids in Gastrointestinal Diseases

  2025cited by this paper
• Environmental and Familial Risk Factors for Multiple Sclerosis: Insights from a Saudi Arabian Cohort

  2025cited by this paper
• Gut microbiota and metabolites are linked to disease progression in multiple sclerosis

  2025cited by this paper
• Game of microbes: the battle within – gut microbiota and multiple sclerosis

  2024cited by this paper
• Gut-associated lymphoid tissue: a microbiota-driven hub of B cell immunity

  2024cited by this paper
• The Immunomodulatory Potential of Short-Chain Fatty Acids in Multiple Sclerosis

  2024cited by this paper
• The potential of short-chain fatty acid epigenetic regulation in chronic low-grade inflammation and obesity

  2024cited by this paper
• Multiple Sclerosis and Other Acquired Demyelinating Diseases of the Central Nervous System.

  2024cited by this paper
• Identification of commensal gut microbiota signatures as predictors of clinical severity and disease progression in multiple sclerosis

  2024cited by this paper
• Life history of a brain autoreactive T cell: From thymus through intestine to blood-brain barrier and brain lesion

  2024cited by this paper
• The Role of Short Chain Fatty Acids in Inflammation and Body Health

  2024cited by this paper
• Butyrate producers, “The Sentinel of Gut”: Their intestinal significance with and beyond butyrate, and prospective use as microbial therapeutics

  2023cited by this paper
• Feeding the gut microbiome: impact on multiple sclerosis

  2023cited by this paper
• Short-Chain Fatty Acids—A Product of the Microbiome and Its Participation in Two-Way Communication on the Microbiome-Host Mammal Line

  2023cited by this paper
• Immunomodulatory Effects of Microbiota-Derived Short-Chain Fatty Acids in Autoimmune Liver Diseases.

  2023cited by this paper
• Gut microbiome-modulated dietary strategies in EAE and multiple sclerosis

  2023cited by this paper
• Gut-Microbiota-Derived Metabolites Maintain Gut and Systemic Immune Homeostasis

  2023cited by this paper
• The interplay between T helper cells and brain barriers in the pathogenesis of multiple sclerosis

  2023cited by this paper
• Sirtuins and redox signaling interplay in neurogenesis, neurodegenerative diseases, and neural cell reprogramming

  2023cited by this paper
• Gut Microbial-Derived Metabolites as Immune Modulators of T Helper 17 and Regulatory T Cells

  2023cited by this paper
• Impact of Disease-Modifying Therapies on Gut–Brain Axis in Multiple Sclerosis

  2023cited by this paper
• Disease-modifying therapies used to treat multiple sclerosis and the gut microbiome: a systematic review

  2023cited by this paper
• Gut flora in multiple sclerosis: implications for pathogenesis and treatment

  2023cited by this paper
• Targeting gut microbiota: new therapeutic opportunities in multiple sclerosis

  2023cited by this paper
• The effect of probiotic supplementation on the clinical and para-clinical findings of multiple sclerosis: a randomized clinical trial

  2023cited by this paper
• Astrogliosis in multiple sclerosis and neuro-inflammation: what role for the notch pathway?

  2023cited by this paper
• Roles of Short-Chain Fatty Acids in Inflammatory Bowel Disease

  2023cited by this paper
• Emerging Paradigms in Inflammatory Disease Management: Exploring Bioactive Compounds and the Gut Microbiota

  2023cited by this paper
• MiRNA-146a—A Key Player in Immunity and Diseases

  2023cited by this paper
• mTOR Signaling Pathway and Gut Microbiota in Various Disorders: Mechanisms and Potential Drugs in Pharmacotherapy

  2023cited by this paper
• The Role of Gut Microbiome in the Pathogenesis of Multiple Sclerosis and Related Disorders

  2023cited by this paper
• Signalling cognition: the gut microbiota and hypothalamic-pituitary-adrenal axis

  2023cited by this paper
• Effects of gut microbiota on neurodegenerative diseases

  2023cited by this paper
• Disease modifying therapies for multiple sclerosis: benefit and acceptability

  2022cited by this paper
• Efficacy and Safety of Multiple Sclerosis Drugs Approved Since 2018 and Future Developments

  2022cited by this paper
• Fatty acids role in multiple sclerosis as “metabokines”

  2022cited by this paper
• Thinking outside the box: non-canonical targets in multiple sclerosis

  2022cited by this paper
• Posttranslational modifications of proteins are key features in the identification of CSF biomarkers of multiple sclerosis

  2022cited by this paper
• Perturbations in gut microbiota composition in psychiatric disorders: a review and meta­analysis

  2022cited by this paper
• Role of Long Noncoding RNAs in the Regulation of Cellular Immune Response and Inflammatory Diseases

  2022cited by this paper
• Alterations of host-gut microbiome interactions in multiple sclerosis

  2022cited by this paper
• Microbiota-derived short chain fatty acids modulate microglia and promote Aβ plaque deposition

  2021cited by this paper
• The Role of Molecular Imaging as a Marker of Remyelination and Repair in Multiple Sclerosis

  2021cited by this paper
• The Immunomodulatory Functions of Butyrate

  2021cited by this paper
• Potential Biomarkers Associated with Multiple Sclerosis Pathology

  2021influential reference
• Perturbations in Gut Microbiota Composition in Psychiatric Disorders

  2021cited by this paper
• Disease-modifying therapies and progressive multifocal leukoencephalopathy in multiple sclerosis: A systematic review and meta-analysis.

  2021cited by this paper
• Targeting the gut to treat multiple sclerosis.

  2021cited by this paper
• Long Chain Fatty Acids as Modulators of Immune Cells Function: Contribution of FFA1 and FFA4 Receptors

  2021cited by this paper
• The multiple sclerosis prodrome

  2021cited by this paper
• Serum Short-Chain Fatty Acids and Associations With Inflammation in Newly Diagnosed Patients With Multiple Sclerosis and Healthy Controls

  2021cited by this paper
• Dysbiosis and Alzheimer’s Disease: A Role for Chronic Stress?

  2021cited by this paper
• Gut Microbiome in Progressive Multiple Sclerosis

  2021cited by this paper
• Short chain fatty acids and its producing organisms: An overlooked therapy for IBD?

  2021cited by this paper
• Altered in vivo brain GABA and glutamate levels are associated with multiple sclerosis central fatigue.

  2021cited by this paper
• Interaction between microbiota and immunity in health and disease

  2020cited by this paper
• The impact of maternal and early life malnutrition on health: a diet-microbe perspective

  2020cited by this paper
• The Effect of Probiotics on the Production of Short-Chain Fatty Acids by Human Intestinal Microbiome

  2020cited by this paper
• Short-chain fatty acids (SCFAs) alone or in combination regulate select immune functions of microglia-like cells.

  2020cited by this paper
• Clinical presentation and diagnosis of multiple sclerosis.

  2020cited by this paper
• The Short Overview on the Relevance of Fatty Acids for Human Cardiovascular Disorders

  2020cited by this paper
• The Role of Short-Chain Fatty Acids From Gut Microbiota in Gut-Brain Communication

  2020cited by this paper
• CSF biomarkers in multiple sclerosis: beyond neuroinflammation

  2020cited by this paper
• Metabolomic Biomarkers of Multiple Sclerosis: A Systematic Review

  2020cited by this paper
• Reproducibility of Glutamate, Glutathione, and GABA Measurements in vivo by Single-Voxel STEAM Magnetic Resonance Spectroscopy at 7-Tesla in Healthy Individuals

  2020cited by this paper
• Rising prevalence of multiple sclerosis worldwide: Insights from the Atlas of MS, third edition

  2020influential reference
• Gut microbiota in human metabolic health and disease

  2020cited by this paper
• Short-chain fatty acids and intestinal inflammation in multiple sclerosis: modulation of female susceptibility by microbial products?

  2020cited by this paper
• Propionic Acid Shapes the Multiple Sclerosis Disease Course by an Immunomodulatory Mechanism.

  2020cited by this paper
• Alterations in Circulating Fatty Acid Are Associated With Gut Microbiota Dysbiosis and Inflammation in Multiple Sclerosis

  2020cited by this paper
• MicroRNAs (miRNAs) and Long Non-Coding RNAs (lncRNAs) as New Tools for Cancer Therapy: First Steps from Bench to Bedside

  2020cited by this paper
• Acetate Promotes T Cell Effector Function during Glucose Restriction.

  2019cited by this paper
• Butyrate suppresses demyelination and enhances remyelination

  2019cited by this paper
• Multiple sclerosis genomic map implicates peripheral immune cells and microglia in susceptibility

  2019cited by this paper
• Recent advances in understanding multiple sclerosis

  2019cited by this paper
• Biomarkers in Multiple Sclerosis.

  2019cited by this paper
• Author response: Postconvulsive central apnea as a biomarker for sudden unexpected death in epilepsy (SUDEP)

  2019cited by this paper
• Author Correction: Bidirectional regulatory potentials of short-chain fatty acids and their G-protein-coupled receptors in autoimmune neuroinflammation

  2019cited by this paper
• The Role of B Cells and Antibodies in Multiple Sclerosis, Neuromyelitis Optica, and Related Disorders

  2019cited by this paper
• Short Chain Fatty Acids (SCFAs)-Mediated Gut Epithelial and Immune Regulation and Its Relevance for Inflammatory Bowel Diseases

  2019cited by this paper
• Microbiota Metabolite Butyrate Differentially Regulates Th1 and Th17 Cells' Differentiation and Function in Induction of Colitis.

  2019cited by this paper
• Multiple Sclerosis Risk Factors and Pathogenesis.

  2019cited by this paper
• Impact of sex hormones on immune function and multiple sclerosis development

  2018cited by this paper
• Optical coherence tomography in multiple sclerosis

  2018cited by this paper
• Mitochondrial dysfunction and axon degeneration in progressive multiple sclerosis

  2018cited by this paper
• Regulation of neuronal development and function by ROS

  2018cited by this paper
• Worldwide prevalence of familial multiple sclerosis: A systematic review and meta-analysis.

  2018influential reference

• From Microbiota to Metabolomics: How Corylus heterophylla Fisch. Male Flower Extract Shields Mice from Cognitive Decline

  2025cites this paper